Active Biotech - Notice of Annual General Meeting of Shareholders

| Source: Active Biotech AB
The Board of Directors of Active Biotech AB (publ) has issued a notice to the
Annual General Meeting, which is to take place at 5 p.m. on Thursday, May
15, 2014, at 5 pm at Elite Hotel Ideon, Scheelevägen 27 in Lund, Sweden.

Please see the attached notification, which is being announced within short in
Svenska Dagbladet and Post- och Inrikes Tidningar.

Lund, April 14, 2014


Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod (Nerventra®), an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In addition, laquinimod Phase II clinical trials in Crohn's and Lupus has been
concluded. The company also has one additional project in clinical development,
the orally administered compound paquinimod (57-57) for systemic sclerosis.
Please visit for more information.

Active Biotech AB
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 08:30 a.m. CET on April 14, 2014.